middle.news
Starpharma Secures $8.5M Genentech Deal, Eyes $564M Milestones
9:04am on Tuesday 28th of October, 2025 AEDT
•
Biotechnology
Read Story
Starpharma Secures $8.5M Genentech Deal, Eyes $564M Milestones
9:04am on Tuesday 28th of October, 2025 AEDT
Key Points
Collaboration and license agreement with Genentech including $8.5M upfront
Research and option agreement with Radiopharm Theranostics with $2M potential upfront
Up to $564M and $89M in success-based milestone payments respectively
DEP® HER2 radiopharmaceuticals program progressing to first-in-patient trial in 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma Holdings (ASX:SPL)
OPEN ARTICLE